Toyama, Tetsuo <br/><br/>
Therapeutic Targeting of TAZ and YAP by Dimethyl Fumarate in Systemic Sclerosis Fibrosis.  [electronic resource] 

 -  The Journal of investigative dermatology  01 2018 
 - 78-88 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1523-1747 
<br/><br/><label>Standard No.: </label>10.1016/j.jid.2017.08.024  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adaptor Proteins, Signal Transducing--metabolism<br/>Adult<br/>Animals<br/>Biopsy<br/>Bleomycin--toxicity<br/>Cell Cycle Proteins<br/>Cell Nucleus--metabolism<br/>Cells, Cultured<br/>Dimethyl Fumarate--pharmacology<br/>Disease Models, Animal<br/>Female<br/>Fibroblasts<br/>Fibrosis<br/>Humans<br/>Intracellular Signaling Peptides and Proteins--metabolism<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>Middle Aged<br/>Phosphatidylinositol 3-Kinase--metabolism<br/>Phosphoproteins--metabolism<br/>Proteolysis--drug effects<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Scleroderma, Systemic--drug therapy<br/>Signal Transduction--drug effects<br/>Skin--drug effects<br/>Trans-Activators<br/>Transcription Factors<br/>Transcriptional Coactivator with PDZ-Binding Motif Proteins<br/>Transforming Growth Factor beta--metabolism<br/>Treatment Outcome<br/>YAP-Signaling Proteins